Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
The plasma kallikrein-kinin system counterbalances the renin-angiotensin system
Alvin H. Schmaier
Alvin H. Schmaier
Published April 15, 2002
Citation Information: J Clin Invest. 2002;109(8):1007-1009. https://doi.org/10.1172/JCI15490.
View: Text | PDF
Commentary

The plasma kallikrein-kinin system counterbalances the renin-angiotensin system

  • Text
  • PDF
Abstract

Authors

Alvin H. Schmaier

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
Assembly and activation of the plasma KKS on endothelial cells. Plasma P...
Assembly and activation of the plasma KKS on endothelial cells. Plasma PK circulates in complex with HK. The HK•PK complex binds to a multiprotein receptor complex that consists of cytokeratin 1 (CK1), urokinase plasminogen activator receptor (uPAR) and gC1qR. The proteins of the HK•PK receptor complex co-localize on endothelial cell membranes. When HK•PK binds to endothelial cells, PK is rapidly converted to kallikrein (K) by the enzyme prolylcarboxypeptidase (PRCP), which is constitutively active on endothelial cell membranes. The resulting kallikrein autodigests its receptor, HK, to liberate bradykinin (BK), which can liberate tissue plasminogen activator (tPA), nitric oxide (NO), and prostacyclin (PGI2) from endothelial cells. Kallikrein also activates FXII, which binds to the same multiprotein receptor complex as HK in its absence. In this revised hypothesis for assembly and activation of the proteins of the plasma KKS, FXII is activated by kallikrein after PK activation. ScuPA, single chain urokinase plasminogen activator.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts